Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats.

@article{Eren2014EffectsOP,
  title={Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats.},
  author={Zehra Eren and Mehmet Yalçin G{\"u}nal and Elif Arı Bakir and Jale Çoban and Berrak Çağlayan and Nur Ekimci and Sinem Ethemoglu and Ozgur Albayrak and Tuba Akdeniz and G{\"u}lderen Yanikkaya Demirel and Ertugrul Kilic and G{\"u}lçin Kantarci},
  journal={Kidney & blood pressure research},
  year={2014},
  volume={39 6},
  pages={581-90}
}
BACKGROUND/AIMS The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats. METHODS Forty male Sprague Dawley rats were divided into 5 groups of 8 rats each, namely the control (Group C), diabetes (Group D), aliskiren (Group A), paricalcitol (Group P), and aliskiren plus paricalcitol (Group A+P) groups. Aliskiren was given by oral-gavage at a dose of 50 mg/kg/day once daily for 12 weeks… CONTINUE READING
6 Citations
37 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Lizakowski B: Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions

  • L Tylicki
  • J Nephrol 2012;25:900-910
  • 2012

Similar Papers

Loading similar papers…